AHCO vs AZN
AdaptHealth Corp. vs ASTRAZENECA PLC — Side-by-Side Stock Comparison
AHCO
AdaptHealth Corp.
4.7
Weak
$11.85
AZN
ASTRAZENECA PLC
8.4
Strong Buy
$200.99
AHCO vs AZN: Which is the Better Investment?
AdaptHealth Corp. (AHCO) scores 4.7/10 while ASTRAZENECA PLC (AZN) scores 8.4/10 on AlphaStocks' composite model. ASTRAZENECA PLC has the higher composite rating of Strong Buy.
This comparison is algorithmically generated and is not financial advice.
| Metric | AHCO | AZN |
|---|---|---|
| Scores & Fundamentals | ||
| Composite Score | 4.7/10 | 8.4/10▲ |
| Rating | Weak | Strong Buy▲ |
| Price | $11.85 | $200.99 |
| P/E Ratio | — | 30.4 |
| ROE | -4.5% | 21.9%▲ |
| Market Cap | $2B | $312B |
| Fair Value | $11.82 | $192.63 |
| Dividend Yield | — | 1.6% |
| Sector Rank | #663 of 1127 | #3 of 1127▲ |
| Model Verdicts | ||
| Piotroski | Attractive | Strong▲ |
| Buffett | Caution | Strong▲ |
| Graham | Caution | Caution |
| Lynch | Caution | Neutral▲ |
| Greenblatt | Caution | Neutral▲ |
AHCO vs AZN: Which Stock Scores Higher?
AdaptHealth Corp. (AHCO) and ASTRAZENECA PLC (AZN) are among the most compared stocks in the Health Care sector. AZN currently leads with a composite score of 8.4/10 (Strong Buy) compared to AHCO's 4.7/10 (Weak).
The AlphaStocks composite score evaluates each stock across four dimensions: Quality (business strength measured by Piotroski F-Score and Buffett quality criteria), Value (discount to intrinsic worth using Graham, Lynch, and Greenblatt models), Momentum (6-month price trend), and Timing (a confirmation signal that requires both value and momentum to align). A higher composite score indicates stronger overall fundamentals combined with favorable market conditions.
This comparison uses the same scoring framework for both companies, ensuring an apples-to-apples evaluation. Scores are recalculated daily after market close using data from SEC filings and market prices. Read the full methodology to understand how each model contributes to the composite score.
Scores are algorithm-generated research tools, not investment recommendations. Past performance does not guarantee future results. Always do your own due diligence. Full disclaimer